DUBLIN – Shares in several European antibody developers, including Affimed NV, Argenx SE and Morphosys AG, posted healthy gains Thursday on the release of abstracts in advance of the 60th annual meeting of the American Society of Hematology (ASH), which kicks off on Dec. 1 in San Diego.